• Carlos Gil Ferreira, Maria Isabel Achatz, Patricia Ashton-Prolla, Maria Dirlei Begnami, Fabricio K Marchini, and Stephen Doral Stefani.
• D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil. Electronic address: cgmferreira@gmail.com.
• Lancet Oncol. 2016 Aug 1; 17 (8): e363-70.

AbstractA growing understanding of the molecular pathology of tumours combined with a surge of new drugs and associated diagnostic technologies (ie, precision medicine) has translated into substantial improvements in survival for patients with cancer. However, to achieve the promise that precision medicine has to offer will require overcoming hurdles within a national health-care system in which it is to be implemented. Brazil is one such nation, an emerging middle-income country with a very complex health-care system. To address the challenges associated with implementing precision medicine into a country such as Brazil, a group of experts convened (Nov 16-18, 2015, Miami) to discuss challenges related to precision medicine within an oncology setting. Complex regulatory hurdles, a shortage of human and technical resources, and the complexities of a two-tiered health-care delivery system were all identified as the main shortcomings to effectively implementing this new field of medicine. A path forward was proposed that relies on active collaboration between clinicians, private organisations, and government. It seems entirely possible that, despite many intrinsic economic and political problems, Brazil can readily emerge as a model for other countries in Latin America for the potential benefits of precision medicine and companion diagnostics.Copyright © 2016 Elsevier Ltd. All rights reserved.

15 keywords...

hide…